Fibromyalgia Trial, Recruiting NCT07390851 Sponsor: Cairo University Condition: Fibromyalgia
Back to Fibromyalgia

Fibromyalgia Trial, Recruiting

NCT07390851
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 70 years old.
  • You have been diagnosed with Myofascial Pain Dysfunction Syndrome (MPDS), a condition involving muscle pain and tension in the jaw and surrounding areas.
  • You have painful, sensitive "knots" in muscles such as the jaw, temple, or upper shoulder that a doctor can locate and access.
  • Your pain has been ongoing for at least 3 months.
  • Your pain level is 4 or higher on a 10-point pain scale.
  • You have not had any trigger point injections in the affected area in the last 3 months.
  • You are able and willing to sign a consent form agreeing to take part in the study.
  • You are able to attend all required study appointments and follow the study procedures.

Who may not be able to join:

  • You have a known allergy to Lidocaine, Magnesium Sulfate, or similar medicines.
  • You are currently taking blood-thinning medication or have a condition that affects your blood's ability to clot.
  • You have an active infection at or near the area where injections would be given.
  • You have a history of fibromyalgia, widespread nerve-related pain conditions, or pain caused by cancer.
  • You have a serious mental health condition, such as schizophrenia or severe depression.
  • You have had surgery or a significant injury to your head, neck, or upper back within the last 6 months.
  • You have taken pain-relief medicines such as anti-inflammatories or opioids within the 5 days before the treatment.
  • You have a serious ongoing health condition, such as uncontrolled diabetes, liver or kidney failure, or a severe heart condition.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Maii E Abdelazeem, Bsc, Faculty of Oral & Dental Medicine, Cairo University

Phone: +20 1013988933

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
26 November 2025
Est. completion
26 November 2026

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

Pain reduction.; Muscle activity improvement.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov